Re: Multi-institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F20%3A10414006" target="_blank" >RIV/00216208:11130/20:10414006 - isvavai.cz</a>
Alternative codes found
RIV/00064203:_____/20:10414006
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=ZPXKWDKP5T" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=ZPXKWDKP5T</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.eururo.2020.04.020" target="_blank" >10.1016/j.eururo.2020.04.020</a>
Alternative languages
Result language
angličtina
Original language name
Re: Multi-institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer
Original language description
High-grade recurrence after BCG instillation therapy for NMIBC is associated with a significant risk of tumour progression. Radical cystectomy is recommended for these patients to prevent disease spread and tumour-related death. As radical cystectomy is associated with a risk of complications and overtreatment, an effective bladder-preserving treatment modality is desired. Steinberg et al present outcomes from one of the largest multicentre cohort of patients with recurrence after BCG immunotherapy. The results are promising, but there are some aspects that need to be discussed.
Czech name
—
Czech description
—
Classification
Type
O - Miscellaneous
CEP classification
—
OECD FORD branch
30217 - Urology and nephrology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů